Iacone previously served as director and global head of the rare diseases research division at Swiss pharma giant Roche, where he was responsible for generating disease area strategies and advancing several assets for immunological and neurological disease from discovery to early clinical development.
Arix said the new role will see Iacone sourcing potential investment opportunities that the company can jointly fund with its partner Takeda Ventures, the strategic venture investing arm of Takeda Pharmaceuticals.
“Roberto brings a wealth of international experience and excellent track record of creating companies that foster exciting science. He will be a valuable addition to Arix and Takeda as we work together to create innovative new companies that address serious medical need”, said Arix chief executive Joe Anderson.
Arix shares were steady at 78.5p in lunchtime trading on Monday.